Assessment of Cardiac and Pulmonary Function in Adult Patients with Hodgkin's Disease Treated with ABVD or MOPP/ABVD Plus Adjuvant Low-Dose Mediastinal Irradiation

References

• Hancock S L, Hoppe R T, Homing S J, et al. Inter current death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials. Ann Intern Med 1988; 109: 183–189
   PubMed Web of Science ®Google Scholar
• Hancock S L, Cox R S, Homing S, et al. Correction: Death after treatment of Hodgkin's disease. Ann Intern Med 1991; 114: 810
   Web of Science ®Google Scholar
• Boivin J F, Hutchison G B, Lyden M, et al. Second primary cancers following treatment of Hodgkin's disease. J Natl Cancer Inst 1984; 72: 233–241
   PubMed Web of Science ®Google Scholar
• Valagussa P, Santoro A, Fossati-Bellani F, et al. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986; 4330–837
   Google Scholar
• Tucker M A, Coleman C N, Cox R S, et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988; 318: 76–81
   PubMed Web of Science ®Google Scholar
• Swerdlow A J, Douglas A J, Vaughan Hudson G, et al. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ 1992; 304: 1137–1143
   PubMed Web of Science ®Google Scholar
• Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol 1992; 4: 117–128
   Google Scholar
• Boice J J. Second cancer after Hodgkin's disease—the price of success?. J Natl Cancer Inst 1993; 85: 4–5, (editorial)
   PubMed Web of Science ®Google Scholar
• Abrahamsen J F, Andersen A, Hannisdal E, et al. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol 1993; 11: 255–261
   PubMed Web of Science ®Google Scholar
• Hancock S L, Tucker M A, Hoppe R T. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993; 85: 25–31
   PubMed Web of Science ®Google Scholar
• van Leeuwen F E, Klokman W J, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994; 12: 312–25
   PubMed Web of Science ®Google Scholar
• Dona R, Holford T, Farber L R, et al. Second solid malignancies after combined modality therapy for Hodgkin's disease. J Clin Oncol 1995; 13: 2016–2022
   PubMed Web of Science ®Google Scholar
• Bhatia S, Robinson L L, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996; 34: 745–751
   Google Scholar
• Boivin J F, Hutchison G B, Lubin J H, et al. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992; 69: 1241–1247
   PubMed Web of Science ®Google Scholar
• Hancock S L, Tucker M A, Hoppe R T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270: 1949–1955
   PubMed Web of Science ®Google Scholar
• Mauch P M, Kalish L A, Chayt Marcus K, et al. Long-term survival in Hodgkin's disease. Relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1995; 1: 33–42
   PubMedGoogle Scholar
• Rodriguez M A, Fuller L M, Zimmerman S O, et al. Hodgkin's disease: study of treatment intensities and incidence of second malignancies. Ann Oncol 1993; 4: 125–131
   PubMed Web of Science ®Google Scholar
• Kaldor J M, Day N E, Bell J, et al. Lung cancer following Hodgkin's disease: a case-control study. Int J Cancer 1992; 52: 677–681
   PubMed Web of Science ®Google Scholar
• Fabian C J, Mansfield C M, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med 1994; 120: 903–912
   PubMed Web of Science ®Google Scholar
• Fryer C J, Hutchinson R J, Krailo M, et al. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children Cancer Study Group. J Clin Oncol 1990; 8: 1971–1980
   PubMed Web of Science ®Google Scholar
• Hunger S P, Link M P, Donaldson S S. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stamford experience. J Clin Oncol 1994; 12: 2160–2166
   PubMed Web of Science ®Google Scholar
• Hudson M M, Greenwald C, Thompson E, et al. Efficacy and toxicity multiagent chemotherapy and low-dose involved field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol 1993; 11: 100–108
   PubMed Web of Science ®Google Scholar
• Dionet C, Oberlin O, Habrand J L, et al. Initial chemotherapy and low-dose radiation in limited fields in childhood Hodgkin's disease: results of a joint cooperative study by the French Society of Pediatric Oncology (SFOP) and Hôpital Saint-Louis, Paris. Int J Rad Biol Phys 1991; 15: 341–346
   Google Scholar
• Weiner M A, Leventhal B G, Marcus R, et al. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group Study. J Clin Oncol 1991; 9: 1591–1598
   PubMed Web of Science ®Google Scholar
• Salloum E, Dona R, Schubert W, et al. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 1996; 14: 2435–2443
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vin-blastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252–259
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8 year results. Ann Intern Med 1986; 104: 739–746
   PubMed Web of Science ®Google Scholar
• Lukes R J, Butler J J, Hicks E. Natural history of Hodgkin's disease as related to its pathologic picture. Cancer 1966; 19: 317–344
   Web of Science ®Google Scholar
• Cdahan R J, Froelich J W, McKusick K A, et al. A modified method for the in vivo labelling of red blood cells with Tc-99m: concise communication. J Nucl Med 1982; 23: 315–318
   PubMed Web of Science ®Google Scholar
• Lee F A, Fetterman R, Zaret B L, et al. Rapid radionuclide derived systolic and diastolic cardiac function using cycle-dependent background correction and Fourier analysis. Proceedings of Computers in Cardiology September, 1985; 443–446
   Google Scholar
• Massardo T, Gal R A, Genier R P, et al. Left ventricular volume calculation using a count-based ratio method applied to multigated radionuclide angiography. J Nucl Med 1990; 31: 450–456
   PubMed Web of Science ®Google Scholar
• Crapo R O, Moms A H, Gardner R M. References values for pulmonary tissue volume, membrane diffusing capacity, and pulmonary capillary blood volume. Bull Eur Physiopathol Resp 1982; 18: 893–899
   PubMedGoogle Scholar
• Ogilvie C M, Forster R E, Blakemore W S, et al. A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide. J CLin Invest 1957; 36: 1–17
   PubMed Web of Science ®Google Scholar
• Bates D, Macklem P, Christie R. An introduction to the integrated study of the lung. Respiratory Function in Disease, D Bates, P Macklem, R Christie. WB Saunders, Philadelphia 1971; 93–94
   Google Scholar
• SAS Institute Inc. SAS Technical Report P- 179, additional SASl STAT Procedures. SAS Institute Inc., Cary, NS 1988, Release 6.03.
   Google Scholar
• Evans R F, Sageman R H, Ringrose T L, et al. Pulmonary function following mantle-field irradiation for Hodgkin's disease. Radiology 1974; 111: 729–731
   PubMed Web of Science ®Google Scholar
• Homing S J, Adhikari A, Rizk N, et al. Effect of treatment for Hodgkin' s disease on pulmonary function: results of a prospective study. J Clin Oncol 1994; 12: 297–305
   PubMed Web of Science ®Google Scholar
• Hirsch A, Vander Els N, Straus D J, et al. Effect of ABVD chemotherapy with or without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 1996; 14: 1297–1305
   PubMed Web of Science ®Google Scholar
• Cosset I M, Henry-Amar M, Meenvaldt J H. Long-term toxicity of early-stages of Hodgkin's disease therapy: the EORTC experience. Ann Oncol 1991; 2: 77–82
   PubMed Web of Science ®Google Scholar
• Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 27–37
   PubMed Web of Science ®Google Scholar
• Bates N P, Williams M V, Bessell E M, et al. Efficacy and toxicity of vinblastin, bleomycin and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: a British National Lymphoma Investigation pilot study. J Clin Oncol 1994; 12: 288–296
   PubMed Web of Science ®Google Scholar
• Gobbi P G, Pieresca C, Frassoldati A, et al. Vinblastin, bleomycin and methotrexate chemotherapy plus extended field radiotherapy in early, favorably presenting, clinically staged Hodgkin's disease patients: the Gruppo Italiano per lo Studio dei Linfomi Experience. J Clin Oncol 1996; 14: 527–533
   PubMed Web of Science ®Google Scholar
• Homing S J, Hoppe R, Rosenberg S A. VBM: an effective adjuvant in favorable Hodgkin's disease. J Clin Oncol 1988; 6: 1822–1831
   PubMed Web of Science ®Google Scholar
• Einhorn L, Krause M, Hornback N, et al. Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer. Cancer 1976; 37: 2414–2416
   PubMed Web of Science ®Google Scholar
• Samuels M L, Johnson D E, Holoye P Y, et al. Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy. JAMA 1976; 235: 1117–1120
   PubMed Web of Science ®Google Scholar
• Yarnold J R, Horwich A, Duchesne G, et al. The influence of sequence and timing of drugs and radiation on the appearance of normal tissue damage. Radiother Oncol 1983; 1: 91–99
   PubMedGoogle Scholar
• Lipshultz S E, Lipsitz S R, Mone S M, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738–1743
   PubMed Web of Science ®Google Scholar